Interferon-gamma-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo.
To investigate the immunoregulatory effect of murine interferon-gamma-inducing factor (mIGIF), we transfected Lewis lung carcinoma (LLC) cells with a mammalian expression vector containing the mIGIF complementary DNA. The culture medium of the transfectant cells stimulated interferon-gamma (IFN-gamma) production by spleen cells in vitro in the presence of anti-CD3 antibody and markedly potentiated the effect of interleukin-12 (IL-12) on IFN-gamma production by spleen cells. mIGIF transfectant cells showed reduction of tumorigenicity and induction of an in vivo immuno-protective effect against the parental LLC cells. To examine the combined effect of systemic administration of recombinant IL-12 (rIL-12) and local mIGIF on the tumorigenicity, mice were challenged with LLC or transfectant cells on day 0, and the tumor-bearing mice were injected with 50 ng of rIL-12 intraperitoneally from day 7 to 11. Systemic rIL-12 showed an anti-tumor effect. However, mIGIF gene expression did not potentiate this effect of systemic rIL-12 in vivo.
Fukumoto
H
H
Pharmacology Division, National Cancer Center Research Institute, Tokyo.
Nishio
M
M
Nishio
K
K
Heike
Y
Y
Arioka
H
H
Kurokawa
H
H
Ishida
T
T
Fukuoka
K
K
Nomoto
T
T
Ohe
Y
Y
Saijo
N
N
D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000276:immunology* / Q000517:prevention & control; D002478:Cells, Cultured; D016207:Cytokines / Q000235:genetics* / Q000276:immunology*; D018076:DNA, Complementary; D004347:Drug Interactions; D007114:Immunization; D007369:Interferon Inducers; D018664:Interleukin-12 / Q000276:immunology / Q000494:pharmacology; D020382:Interleukin-18; D051379:Mice; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000494:pharmacology; D013154:Spleen / Q000378:metabolism; D014162:Transfection
D016207:Cytokines; D018076:DNA, Complementary; D007369:Interferon Inducers; D020382:Interleukin-18; D011994:Recombinant Proteins; D018664:Interleukin-12